Exploring the Role of GLP-1s in Treating Polyendocrine Metabolic Ovarian Syndrome
GLP-1 receptor agonists, commonly referred to as GLP-1s, are primarily used to treat type 2 diabetes and obesity. Notable examples include Ozempic and Wegovy, which contain semaglutide, and Mounjaro and Zepbound, which contain tirzepatide. While these medications are effective for diabetes management, only Wegovy and Zepbound are FDA-approved for obesity treatment. Recent studies have suggested that GLP-1s may also assist in managing polyendocrine metabolic ovarian syndrome (PMOS), previously known as polycystic ovary syndrome (PCOS). PMOS is characterized by irregular menstrual cycles, hormonal imbalances, and can co-occur with obesity. A small study published in the Journal of Clinical Medicine in July 2026 indicated that GLP-1s could aid in weight management and potentially restore ovulatory cycles in individuals with PMOS. This study followed 96 participants with PMOS and a body mass index (BMI) over 25 kg/m2, revealing that 95% of those with mild obesity regulated their menstrual cycles after six months of semaglutide treatment, while only 25% of those with moderate to severe obesity experienced similar results. However, a systematic review published in the European Journal of Endocrinology in February 2026 highlighted that evidence supporting GLP-1s for PMOS treatment is mixed and uncertain. This review analyzed 17 articles and 11 randomized controlled trials, concluding that while overweight individuals with PMOS may lose weight with GLP-1 treatment, the effects on other metabolic outcomes remain unclear. Experts Clare Thompson, MBBS, and Steven Vasilev, MD, discussed the metabolic pathways shared between PMOS, diabetes, and obesity. They noted that PMOS is associated with hyperandrogenism and hyperinsulinemia, which can disrupt ovulation. They suggested that weight loss and GLP-1 treatments could help regulate ovulation by addressing excess estrogen stored in fatty tissues. However, they cautioned that GLP-1s should not be seen as a first-line treatment for PMOS, especially for those not overweight. Both experts emphasized that individuals seeking to conceive should avoid GLP-1s due to their teratogenicity concerns. They also highlighted potential gastrointestinal side effects associated with GLP-1 use, such as nausea and vomiting, which should not be underestimated. Furthermore, they pointed out that current evidence does not support GLP-1s as a primary treatment for PMOS, as lifestyle optimization and other medications remain the preferred options. The discussion extends to the potential use of GLP-1s for other reproductive system conditions, but the evidence is still insufficient. Overall, while GLP-1s show promise for some individuals with PMOS, more research is needed to determine their efficacy and safety in this context.




